Muscle GrowthAnti-AgingFat LossNo data

Ipamorelin + CJC-1295

Ipamorelin Acetate + Modified GRF 1-29

Overview

The Ipamorelin and CJC-1295 combination is one of the most widely used GH-stimulating peptide protocols in the research and wellness community. Ipamorelin provides a clean selective GHRP effect stimulating GH release without significant cortisol or prolactin elevation while CJC-1295 (with or without DAC) amplifies and extends the GH pulse. Together they produce a synergistic GH release response significantly greater than either compound alone making this one of the most popular stacks for muscle growth recovery fat loss and anti-aging applications.

Mechanism of Action

The combination works through complementary pathways in the GH secretion cascade. CJC-1295 binds to GHRH receptors on pituitary somatotrophs priming them to release more GH per pulse and extending the window of GH secretion. Ipamorelin binds to ghrelin receptors (GHSR-1a) amplifying the amplitude of GH pulses and increasing pulsatile frequency. When administered together the two signals converge on pituitary somatotrophs producing a multiplicative rather than simply additive GH release. Ipamorelin's selectivity for GH release without cortisol or prolactin elevation makes it the preferred GHRP partner for CJC-1295 compared to GHRP-6 or GHRP-2 which have more side effects.

Dosage Information

Typical Dose

Ipamorelin: 200-300 mcg + CJC-1295: 100 mcg per dose

Frequency

2-3 times daily, with the most important dose at bedtime

Administration

Subcutaneous injection, both peptides can be combined in one syringe

Notes

Administer on empty stomach — avoid food for 30-40 minutes before and after to maximize GH pulse. Bedtime dose aligns with natural nocturnal GH release. Cycles of 3-6 months typically used.

Where does Ipamorelin + CJC-1295 sit?

See how this peptide compares across all 111 peptides in our database.

Evidence Score

0.07

Clinical trials

0.0035%

Literature

0.0030%

Community

0.0020%

Completeness

0.5015%

Potential Side Effects

Water retention initially (common, resolves)Mild fatigue (common in first 1-2 weeks)Tingling in extremities (uncommon)Increased hunger from Ipamorelin (uncommon)Headache (rare)

Community Experiences

No experiences shared yet. Be the first!

Quick Facts

Administration: Subcutaneous injection, both peptides can be combined in one syringe
Typical Dose: Ipamorelin: 200-300 mcg + CJC-1295: 100 mcg per dose
Frequency: 2-3 times daily, with the most important dose at bedtime
References: 0 curated + 0 from PubMed
Evidence Score: 0.1 / 100